Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

HIF-2alpha inhibitor HS-10516

An orally bioavailable inhibitor of hypoxia inducible factor (HIF)-2alpha, with potential antineoplastic activity. Upon oral administration, HIF-2alpha inhibitor HS-10516 targets and binds to HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate tumor cell growth and survival. Blocking HIF-2alpha reduces the proliferation of HIF-2alpha-expressing tumor cells. HIF-2alpha, a heterodimeric transcription factor overexpressed in many cancer cell types, promotes proliferation, progression and metastasis of tumors.
Synonym:HIF-2-alpha inhibitor HS-10516
HIF2-alpha inhibitor HS-10516
HIF2a inhibitor HS-10516
HIF2alpha inhibitor HS-10516
Code name:HS 10516
HS-10516
HS10516
Search NCI's Drug Dictionary